Featured 13F manager
Gilead Sciences, Inc.
Foster City, CA 4 processed 13Fs on this site · 2025 Q3–2026 Q2
- $1.6B
- 5 Positions
- 2026 Q2
- −22.1% QoQ
- Top 5 100.0%
Gilead Sciences, Inc. files a Form 13F. The latest book is 2026 Q2 at $1.6B, down 22.1% QoQ, led by Arcus Biosciences, Lakefront Biotherapeutics, and Assembly Biosciences.
Portfolio
top 5 100.0% · top 10 100.0%
- RCUS - Arcus Biosciences 58.8%
- LKFT - Lakefront Biotherapeutics 30.3%
- ASMB - Assembly Biosciences 8.3%
- Kyverna Therapeutics 2.2%
- Xilio Therapeutics 0.4%
AUM over time
Book
| RCUS - Arcus Biosciences | 38.69% | Hold | 31,424,760 | $23.83 | $749M | — | — |
| LKFT - Galapagos | 28.45% | Hold | 16,707,477 | $32.96 | $551M | — | — |
| ACLXGBX - Arcellx | 22.64% | Hold | 6,720,803 | $65.20 | $438M | — | — |
| ASMB - Assembly Biosciences | 7.92% | Hold | 4,505,391 | $34.01 | $153M | — | — |
| Kyverna Therapeutics | 2.00% | Hold | 4,126,119 | $9.40 | $39M | — | — |
| Xilio Therapeutics | 0.30% | Hold | 9,105,451 | $0.6402 | $6M | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Merus | 2.38% | Exit | 0 | $94.15 | $43M | −452,527 | −$43M |
| TNGX - Tango Therapeutics | 2.28% | Exit | 0 | $8.40 | $41M | −4,854,443 | −$41M |
| Leap Therapeutics | 0.13% | Exit | 0 | $0.4540 | $2M | −5,319,148 | −$2M |
Filings history
4 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 5 | $1.6B | −22.1% | 13F-HR | 8/3/2026 | 000112329226001034 |
| 2026 Q1 | 6 | $2.1B | +9.4% | 13F-HR | 5/8/2026 | 000112329226000642 |
| 2025 Q4 | 6 | $1.9B | +8.1% | 13F-HR | 2/12/2026 | 000112329226000164 |
| 2025 Q3 | 9 | $1.8B | — | 13F-HR | 11/13/2025 | 000112329225000642 |
About
Gilead Sciences, Inc.
4 processed 13Fs on this site · 2025 Q3–2026 Q2